<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="2886"><DrugName>M-CSF, Genetics Institute/SciGenics</DrugName><DrugSynonyms><Name><Value>M CSF</Value></Name><Name><Value>CSF 1</Value></Name><Name><Value>rhM-CSF</Value></Name><Name><Value>CSF-1, Genetics Institute/SciGenics</Value></Name><Name><Value>CSF-M, Genetics Institute/SciGenics</Value></Name><Name><Value>M-CSF, Genetics Institute/SciGenics</Value></Name><Name><Value>rhGM-CSF, Genetics Institute/SciGenics</Value></Name></DrugSynonyms><CompanyOriginator id="20511">Wyeth BioPharma</CompanyOriginator><CompaniesSecondary><Company id="20511">Wyeth BioPharma</Company><Company id="22671">SciGenics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2886" type="Drug"><TargetEntity id="126552" type="siDrug">Cilmostim</TargetEntity></SourceEntity><SourceEntity id="20511" type="Company"><TargetEntity id="5035523512" type="organizationId">Wyeth Biopharma</TargetEntity></SourceEntity><SourceEntity id="22671" type="Company"><TargetEntity id="4296020897" type="organizationId">Scigenics Inc</TargetEntity></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"/><TargetEntity id="D006937" type="MeSH"/><TargetEntity id="-1478187279" type="omicsDisease"/><TargetEntity id="969" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00510" type="ciTarget"><TargetEntity id="174052253714363" type="siTarget">Macrophage colony-stimulating factor 1 receptor</TargetEntity><TargetEntity id="471" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="174">Hypercholesterolemia</Indication><Indication id="651">Cancer</Indication><Indication id="746">Infectious disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="420">CSF-1 agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1593">Antimicrobial</Action><Action id="71">Antihypercholesterolemic agent</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-02T06:16:19.000Z</LastModificationDate><ChangeDateLast>2017-08-07T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;SciGenics and the Genetics Institute (now &lt;ulink linkID="20511" linkType="Company"&gt;Wyeth BioPharma&lt;/ulink&gt;) were collaborating on the development of recombinant human colony stimulating factor (rhM-CSF) for the potential treatment of hypercholesterolemia. Phase I trials were undertaken in 1993 to investigate its use as a possible treatment for this indication [&lt;ulink linkID="186102" linkType="reference"&gt;186102&lt;/ulink&gt;]; however, no development for this indication has been reported by either company since 1997 [&lt;ulink linkID="495908" linkType="reference"&gt;495908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1994, rhM-CSF was discontinued from development for cancer after phase II trials in over 200 patients. It was also discontinued from development for infectious diseases after being tested in preclinical models of several diseases [&lt;ulink linkID="186102" linkType="reference"&gt;186102&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vitro studies to evaluate the activity of CSF-M in the differentiation and support of myeloid cells has proven interesting with many different effects being observed between its activity and the activity of the closely related cytokines Granulocyte Macrophage CSF (GM-CSF) and interleukin-3 (IL-3).&lt;/para&gt;&lt;para&gt;When added to cultured human monocytes CSF-M was found to support the differentiation and long term survival of macrophage like cells. CSF-M supported macrophages were found to differ in morphology and activity. Morphologically CSF-M treated cells yielded elongated spindle-shaped cells whilst macrophages supported with IL-3 and GM-CSF were found to yield round cells with distinct nuclei. Functionally CSF-M treated cells yielded a larger number of CD14(+) and CD16(+) (Fc gamma RIII) cells than colonies treated with IL-3 or GM-CSF [&lt;ulink linkID="42899" linkType="reference"&gt;42899&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Human peripheral blood monocytes cultured in the presence of CSF-M were found to be more cytotoxic. The antibody dependent cellular cytotoxicity ADCC observed with treated cells was more effective and cytotoxicity was observed at a lower concentration of antibody. No such effects were observed when cells were cultured in the presence of IL-3 or GM-CSF [&lt;ulink linkID="42900" linkType="reference"&gt;42900&lt;/ulink&gt;], [&lt;ulink linkID="42899" linkType="reference"&gt;42899&lt;/ulink&gt;]. The increased level of ADCC may be linked to the higher level of expression of CD16(+) cells [&lt;ulink linkID="42899" linkType="reference"&gt;42899&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo when administered to mice prior to infection with Listeria monocytogenes CSF-M was found to reduce the number of viable Listeria bacteria and improve survival rates [&lt;ulink linkID="42908" linkType="reference"&gt;42908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Investigations into the use of CSF-M in the treatment of autologous bone marrow transplantation revealed that in patients receiving CSF-M the F-actin content of granulocytes was much greater (90%) than that observed in the control group. This observation means that granulocytes which are induced by different cytokines may have different abilities depending upon which cytokine was administered [&lt;ulink linkID="42907" linkType="reference"&gt;42907&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;CSF-M stimulates the growth and activity of macrophages, which are important in the defence against infection and are also involved in cholesterol metabolism. Macrophage CSF (CSF-M) was thought to have a potential role in the treatment of hematological, oncological, immunological and pathogenic disease states. The addition of CSF-M to blood monocytes was also found to augment the production of tumor necrosis factor however this was only achieved when high concentrations of CSF-M were added to the culture [&lt;ulink linkID="42900" linkType="reference"&gt;42900&lt;/ulink&gt;]. CSF-M was not however found to capable of inducing histamine and putrescine formation in mice as was observed with GM-CSF and G-CSF [&lt;ulink linkID="42904" linkType="reference"&gt;42904&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Agreements were made in 1993 with Schering-Plough for Europe, Morinaga for Japan, and SciGenics in North America [&lt;ulink linkID="170931" linkType="reference"&gt;170931&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22671">SciGenics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>1993-12-01T00:00:00.000Z</StatusDate><Source id="186102" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22671">SciGenics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="746">Infectious disease</Indication><StatusDate>1993-12-01T00:00:00.000Z</StatusDate><Source id="186102" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>1993-12-01T00:00:00.000Z</StatusDate><Source id="186102" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="746">Infectious disease</Indication><StatusDate>1993-12-01T00:00:00.000Z</StatusDate><Source id="186102" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2003-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22671">SciGenics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2003-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22671">SciGenics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><Source id="186102" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><Source id="186102" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00510"><Name>CSF-1</Name><SwissprotNumbers><Swissprot>P07333</Swissprot><Swissprot>P09581</Swissprot><Swissprot>P13369</Swissprot><Swissprot>Q00495</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="120470" title="SciGenics and Genetics Institute to co-develop M-CSF"/></Deals><PatentFamilies><PatentFamily id="1367919" number="WO-2008084069" title="A method for expanding monocytes."/><PatentFamily id="286869" number="WO-2005097065" title="Composition comprising colony stimulating factor for treatment of a localised bacterial infection and bacterial related disease"/><PatentFamily id="3058560" number="WO-2015164800" title="Compositions and methods for modulating polarization of monocytes"/><PatentFamily id="3065502" number="WO-2015170291" title="Method for expanding adult stem cells from whole blood"/><PatentFamily id="550750" number="WO-2006113889" title="Compositions and methods for modulating interleukin-10"/><PatentFamily id="734682" number="WO-2008011094" title="Cytokine induction of selectin ligands on cells"/><PatentFamily id="866050" number="WO-2008103301" title="Treatment of the eye using macrophages and/or agents able to affect blood vessel morphology"/></PatentFamilies><hasSWOTs>N</hasSWOTs></drugRecordOutput>